Y-mAbs Therapeutics, Inc.

Contributing Author

Recent Articles by Y-mAbs Therapeutics, Inc.

May-28	Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline YMAB GlobeNewswire
May-26	Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting YMAB GlobeNewswire
May-13	Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 YMAB GlobeNewswire
May-13	Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments YMAB GlobeNewswire
May-07	Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA) YMAB GlobeNewswire
May-06	Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 YMAB GlobeNewswire